

Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents M. Abuzahra, M. Pillai, A. Caldera, W. B. Hartley, R. Gonzalez, J. Bobek, H. Dokainish and N. Lakkis *Am J Cardiol* (2008) 102; 401-3
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18678295

Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention A. Aggarwal, D. Dai, J. S. Rumsfeld, L. W. Klein and M. T. Roe *Am J Cardiol* (2008) 101; 1413-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18471451

Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative) D. Alexander, N. Mann, F. S. Ou, E. D. Peterson, E. M. Ohman, W. B. Gibler and M. T. Roe *Am J Cardiol* (2008) 102; 1335-40
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18993151

Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel L. Ang, V. Palakodeti, A. Khalid, S. Tsimikas, Z. Idrees, P. Tran, P. Clopton, N. Zafar, G. Bromberg-Marin, S. Keramati and E. Mahmud *J Am Coll Cardiol* (2008) 52; 1052-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18848137

Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment D. J. Angiolillo, M. A. Costa, S. B. Shoemaker, B. Desai, E. Bernardo, Y. Suzuki, R. K. Charlton, M. M. Zenni, L. A. Guzman and T. A. Bass *Am J Cardiol* (2008) 101; 440-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18312754

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction) analysis E. M. Antman, S. D. Wiviott, S. A. Murphy, J. Voitek, Y. Hasin, P. Widimsky, H. Chandna, W. Macias, C. H. McCabe and E. Braunwald *J Am Coll Cardiol* (2008) 51; 2028-33
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18498956

Optimizing clopidogrel therapy before stent implantation: should clinical setting be taken into account? D. Aradi, A. Vorobcsuk and A. Komocsi *J Am Coll Cardiol* (2008) 52; 1349; author reply 49-50
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18929249

Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial) H. D. Aronow, R. M. Califf, R. A. Harrington, M. Vallee, C. Graffagnino, A. Shuaib, D. J. Fitzgerald, J. D. Easton, F. Van de Werf, H. C. Diener, J. Ferguson, P. J. Koudstaal, P. Amarenco, P.

Theroux, S. Davis and E. J. Topol *Am J Cardiol* (2008) 102; 1285-90

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18993142

Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial H. D. Aronow, S. R. Steinhubl, D. M. Brennan, P. B. Berger and E. J. Topol *Am Heart J* (2009) 157; 369-74

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19185647

Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality S. Banerjee, C. Varghese, J. Samuel, R. A. Weideman, B. B. Little, K. C. Kelly, S. V. Rao, R. F. Reilly and E. S. Brilakis *Am J Cardiol* (2008) 102; 1159-62

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18940284

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis J. S. Berger, C. B. Frye, Q. Harshaw, F. H. Edwards, S. R. Steinhubl and R. C. Becker *J Am Coll Cardiol* (2008) 52; 1693-701

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19007688

Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy O. F. Bertrand, E. Larose, J. Rodes-Cabau, O. Gleeton, I. Taillon, L. Roy, P. Poirier, O. Costerousse and R. D. Larochelliere *Am Heart J* (2009) 157; 164-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19081414

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial P. J. Best, S. R. Steinhubl, P. B. Berger, A. Dasgupta, D. M. Brennan, L. A. Szczech, R. M. Califf and E. J. Topol *Am Heart J* (2008) 155; 687-93

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18371477

Cytochrome P450 2C19 polymorphism and clopidogrel after MI S. Bhattacharyya and R. Rakhit *Lancet* (2009) 373; 1171; author reply 72-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19345825

The association of cigarette smoking with enhanced platelet inhibition by clopidogrel K. P. Bliden, J. Dichiaro, L. Lawal, A. Singla, M. J. Antonino, B. A. Baker, W. L. Bailey, U. S. Tantry and P. A. Gurbel *J Am Coll Cardiol* (2008) 52; 531-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18687246

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis L. Bonello, L. Camoin-Jau, S. Armero, O. Com, S. Arques, C. Burignat-Bonello, M. P. Giacomoni, R. Bonello, F. Collet, P. Rossi, P. Barragan, F. Dignat-George and F. Paganelli *Am J Cardiol* (2009) 103; 5-10

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19101221

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, O. Wittenberg, M. C. Simeoni, P. Barragan, F. Dignat-George and F. Paganelli *J Am Coll Cardiol* (2008) 51; 1404-11

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18387444

Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy L. Bonello, A. De Labriolle, G. Lemesle, D. H. Steinberg, P. Roy, R. Torguson, W. O. Suddath, L. F. Satler, K. M. Kent, A. D. Pichard and R. Waksman *Catheter Cardiovasc Interv* (2008)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19198009

Bivalirudin with provisional glycoprotein IIb/IIIa inhibitors in patients undergoing primary angioplasty in the setting of cardiogenic shock L. Bonello, A. De Labriolle, P. Roy, D. H. Steinberg, T. L. Pinto Slottow, Z. Xue, K. Smith, R. Torguson, W. O. Suddath, L. F. Satler, K. M. Kent, A. D. Pichard and R. Waksman *Am J Cardiol* (2008) 102; 287-91

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18638588

Emergence of the Concept of Platelet Reactivity Monitoring of Response to Thienopyridines L. Bonello, A. De Labriolle, M. Scheinowitz, G. Lemesle, P. Roy, D. H. Steinberg, T. L. Pinto Slottow, R. Pakala, A. D. Pichard, P. Barragan, L. Camoin-Jau, F. Dignat-George, F. Paganelli and R. Waksman *Heart* (2009)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19196732

Impact of a 600-mg loading dose of clopidogrel on 30-day outcome in unselected patients undergoing percutaneous coronary intervention L. Bonello, G. Lemesle, A. De Labriolle, P. Roy, D. H. Steinberg, T. L. Pinto Slottow, Z. Xue, R. Torguson, W. O. Suddath, L. F. Satler, K. M. Kent, A. D. Pichard, J. Lindsay and R. Waksman *Am J Cardiol* (2008) 102; 1318-22

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18993148

Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions S. S. Brar, J. Kim, S. K. Brar, R. Zidegan, M. Ree, I. L. Liu, P. Mansukhani, V. Aharonian, R. Hyett and A. Y. Shen *J Am Coll Cardiol* (2008) 51; 2220-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18534267

What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? B. R. Brodie *Catheter Cardiovasc Interv* (2008) 71; 816-21

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18412079

Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in

ST-segment elevation myocardial infarction S. Cheng, D. A. Morrow, S. Sloan, E. M. Antman and M. S. Sabatine *Circulation* (2009) 119; 1195-202

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19237657

Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy D. P. Chew, Z. Huang, K. S. Pieper, H. White, K. W. Mahaffey, J. J. Ferguson, R. M. Califf and P. G. Aylward *Am Heart J* (2008) 155; 239-44

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18215592

Emerging transcatheter therapies for aortic and mitral disease R. D. Christofferson, S. R. Kapadia, V. Rajagopal and E. M. Tuzcu *Heart* (2009) 95; 148-55

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18519552

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study J. P. Collet, J. S. Hulot, A. Pena, E. Villard, J. B. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano and G. Montalescot *Lancet* (2009) 373; 309-17

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19108880

Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study J. P. Collet, J. Silvain, A. Landivier, M. L. Tanguy, G. Cayla, A. Bellemain, N. Vignolles, S. Gallier, F. Beygui, A. Pena and G. Montalescot *Circulation* (2008) 118; 1225-33

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18765393

Adjusting clopidogrel loading doses according to vasodilator-stimulated phosphoprotein index: on time, too early, or too late? T. Cuisset, C. Frere, J. Quilici, M. C. Alessi and J. L. Bonnet *J Am Coll Cardiol* (2008) 52; 790-1; author reply 91-2

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18718431

Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris T. Cuisset, M. Hamilos, J. Sarma, G. Sarno, E. Wyffels, M.

Vanderheyden, E. Barbato, J. Bartunek, B. De Bruyne and W. Wijns *Am J Cardiol* (2008) 101; 1700-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18549843

Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes O. H. Dabbous, F. A. Anderson, Jr., J. M. Gore, K. A. Eagle, K. A. Fox, R. H. Mehta, R. J. Goldberg, G. Agnelli and P. G. Steg *Heart* (2008) 94; 159-65

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17575335

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an

individual patient data meta-analysis G. De Luca, C. M. Gibson, F. Bellandi, S. Murphy, M. Maioli, M. Noc, U. Zeymer, D. Dudek, H. R. Arntz, S. Zorman, H. M. Gabriel, A. Emre, D. Cutlip, G. Biondi-Zoccai, T. Rakowski, M. Gyongyosi, P. Marino, K. Huber and A. W. van't Hof Heart (2008) 94; 1548-58

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18474534

Interaction between cigarette smoking and clinical benefit of clopidogrel N. R. Desai, J. L. Mega, S. Jiang, C. P. Cannon and M. S. Sabatine J Am Coll Cardiol (2009) 53; 1273-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19358940

Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin M. A. Duzenli, K. Ozdemir, N. Aygul, A. Soylu and M. Tokac Am J Cardiol (2008) 102; 396-400

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18678294

Guidelines for anticoagulant use in acute coronary syndromes J. Eikelboom, G. Guyatt and J. Hirsh Lancet (2008) 371; 1559-61

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18468530

Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial F. Feit, S. V. Manoukian, R. Ebrahimi, C. V. Pollack, E. M. Ohman, M. J. Attubato, R. Mehran and G. W. Stone J Am Coll Cardiol (2008) 51; 1645-52

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18436116

Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial A. Y. Fung, J. Saw, A. Starovoytov, C. Densem, P. Jokhi, S. J. Walsh, R. S. Fox, K. H. Humphries, E. Aymong, D. R. Ricci, J. G. Webb, J. N. Hamburger, R. G. Carere and C. E. Buller J Am Coll Cardiol (2009) 53; 837-45

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19264239

Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease T. Geisler, M. Kapp, K. Gohring-Frischholz, K. Daub, C. Dosch, B. Bigalke, H. Langer, C. Herdeg and M. Gawaz Heart (2008) 94; 743-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17567647

Ensuring appropriate use of antiplatelet agents in the treatment of acute coronary syndromes--have cardiovascular physicians been given enough grace in getting it right? A. H. Gershlick Heart (2008) 94; 135-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18195118

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study M. Gilard, B. Arnaud, J. C. Cornily, G. Le Gal, K. Lacut, G. Le Calvez, J. Mansourati, D. Mottier, J. F. Abgrall and J. Boschat *J Am Coll Cardiol* (2008) 51; 256-60

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18206732

Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes R. P. Giugliano, J. A. White, C. Bode, P. W. Armstrong, G. Montalescot, B. S. Lewis, T. H. A. van, L. G. Berdan, K. L. Lee, J. T. Strony, S. Hildemann, E. Veltri, F. Van de Werf, E. Braunwald, R. A. Harrington, R. M. Califf and L. K. Newby *N Engl J Med* (2009)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19332455

Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents A. M. Gori, R. Marcucci, A. Migliorini, R. Valenti, G. Moschi, R. Panizza, P. Buonamici, G. F. Gensini, R. Vergara, R. Abbate and D. Antoniucci *J Am Coll Cardiol* (2008) 52; 734-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18718420

Adverse events associated with stopping clopidogrel after acute coronary syndrome S. K. Goyal and S. R. Punnam *JAMA* (2008) 299; 2389; author reply 89-90

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18505946

Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study P. A. Gurbel, K. P. Bliden, J. F. Saucedo, T. A. Suarez, J. DiChiara, M. J. Antonino, E. Mahla, A. Singla, W. R. Herzog, A. K. Bassi, T. A. Hennebry, T. B. Gesheff and U. S. Tantry *J Am Coll Cardiol* (2009) 53; 648-57

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19232896

The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention H. S. Gurm, D. E. Smith, J. S. Collins, D. Share, A. Riba, A. J. Carter, T. LaLonde, E. Kline-Rogers, M. O'Donnell, H. Changezi, M. Zughuib, R. Safian and M. Moscucci *J Am Coll Cardiol* (2008) 51; 529-35

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18237680

Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study Y. Han, Y. Li, S. Wang, Q. Jing, Z. Wang, D. Wang, Q. Shu and X. Tang *Am Heart J* (2009) 157; 733-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19332203

Should we monitor platelet function during antiplatelet therapy? P. Hjerdahl *Heart* (2008) 94; 685-7

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation>

n&list_uids=18480343

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome P. M. Ho, T. M. Maddox, L. Wang, S. D. Fihn, R. L. Jesse, E. D. Peterson and J. S. Rumsfeld JAMA (2009) 301; 937-44
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19258584

Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome P. M. Ho, E. D. Peterson, L. Wang, D. J. Magid, S. D. Fihn, G. C. Larsen, R. A. Jesse and J. S. Rumsfeld JAMA (2008) 299; 532-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18252883

Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention R. Iijima, G. Ndrepepa, J. Mehilli, R. A. Byrne, S. Schulz, F. J. Neumann, G. Richardt, P. B. Berger, A. Schomig and A. Kastrati Eur Heart J (2009) 30; 290-6
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19147609

Cardiovascular outcomes after a change in prescription policy for clopidogrel C. A. Jackevicius, J. V. Tu, V. Demers, M. Melo, J. Cox, S. Rinfret, D. Kalavrouziotis, H. Johansen, H. Behlouli, A. Newman and L. Pilote N Engl J Med (2008) 359; 1802-10
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18946065

Chronically anticoagulated patients who need surgery: Can low-molecular-weight heparins really be used to "bridge" patients instead of intravenous unfractionated heparin? M. R. Jaff Catheter Cardiovasc Interv (2009)
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19213061

Comparison of ticagrelor, the first reversible oral P2Y₁₂ receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial S. James, A. Akerblom, C. P. Cannon, H. Emanuelsson, S. Husted, H. Katus, A. Skene, P. G. Steg, R. F. Storey, R. Harrington, R. Becker and L. Wallentin Am Heart J (2009) 157; 599-605
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19332184

Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study Y. H. Jeong, S. W. Lee, B. R. Choi, I. S. Kim, M. K. Seo, C. H. Kwak, J. Y. Hwang and S. W. Park J Am Coll Cardiol (2009) 53; 1101-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19324253

Outcomes associated with combined antiplatelet and anticoagulant therapy S. G. Johnson, K. Rogers, T. Delate and D. M. Witt Chest (2008) 133; 948-54
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation>

n&list_uids=18198244

Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study S. S. Jolly, J. Pogue, K. Haladyn, R. J. Peters, K. A. Fox, A. Avezum, B. J. Gersh, H. J. Rupprecht, S. Yusuf and S. R. Mehta *Eur Heart J* (2008)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18819961

Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk C. D. Joyner, R. J. Peters, R. Afzal, S. Chrolavicius, S. R. Mehta, K. A. Fox, C. B. Granger, M. G. Franzosi, M. Flather, A. Budaj, J. P. Bassand and S. Yusuf *Am Heart J* (2009) 157; 502-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19249421

Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment P. W. Kamphuisen *Eur Heart J* (2008) 29; 1699-700

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18544543

Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment P. P. Karjalainen, S. Vikman, M. Niemela, P. Porela, A. Ylitalo, M. A. Vaittinen, M. Puurunen, T. J. Airaksinen, K. Nyman, T. Vahlberg and K. E. Airaksinen *Eur Heart J* (2008) 29; 1001-10

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18346963

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention A. Kastrati, F. J. Neumann, J. Mehilli, R. A. Byrne, R. Iijima, H. J. Buttner, A. A. Khatib, S. Schulz, J. C. Blankenship, J. Pache, J. Minners, M. Seyfarth, I. Graf, K. A. Skelding, J. Dirschinger, G. Richardt, P. B. Berger and A. Schomig *N Engl J Med* (2008) 359; 688-96

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18703471

Adverse events associated with stopping clopidogrel after acute coronary syndrome D. H. Kim *JAMA* (2008) 299; 2388-9; author reply 89-90

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18505945

Clopidogrel use and bleeding after coronary artery bypass graft surgery J. H. Kim, L. K. Newby, R. M. Clare, L. K. Shaw, A. J. Lodge, P. K. Smith, E. M. Jolicoeur, S. V. Rao, R. C. Becker, D. B. Mark and C. B. Granger *Am Heart J* (2008) 156; 886-92

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19061702

Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention A. S. Kini, V. H. Chen, P. Krishnan, P. Lee, M. C. Kim, A. Mares, J. Suleman, P. R. Moreno and S. K. Sharma *Am Heart J* (2008) 156; 513-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18760134

Comparison of coronary flow reserve and fractional flow reserve in patients with versus

without diabetes mellitus and having elective percutaneous coronary intervention and abciximab therapy (from the PREDICT Trial) A. S. Kini, M. C. Kim, P. R. Moreno, P. Krishnan, O. C. Ivan and S. K. Sharma *Am J Cardiol* (2008) 101; 796-800

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18328843

The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention K. E. Kip, K.

Hollabaugh, O. C. Marroquin and D. O. Williams *J Am Coll Cardiol* (2008) 51; 701-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18279733

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology W. Kulickowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, M. Zembala, G. Opolski, K. Huber, H. Arnesen, S. D. Kristensen and R. De Caterina *Eur Heart J* (2009) 30; 426-35

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19174428

Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study P. L. L'Allier, G. Ducrocq, N. Pranno, S. Noble, R. Ibrahim, J. C. Gregoire, F. Azzari, A. Nozza, C. Berry, S. Doucet, B. Labarthe, P. Theroux and J. C. Tardif *J Am Coll Cardiol* (2008) 51; 1066-72

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18342223

Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial A. J. Lansky, Y. Tsuchiya, M. Brener, R. Mehran, E. Cristea, C. Pietras, C. L. Grines, D. A. Cox, E. Garcia, J. E. Tcheng, G. Guagliumi, T. Stuckey, M. Turco, J. D. Carroll, B. D. Rutherford, M. B. Leon, J. Moses and G. W. Stone *Catheter Cardiovasc Interv* (2008) 72; 917-24

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19016469

Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention G. Lemesle, A. De Labriolle, L. Bonello, A. Syed, S. Collins, G. Maluenda, R. Torguson, K. Kaneshige, Z. Xue, W. O. Suddath, L. F. Satler, K. M. Kent, J. Lindsay, A. D. Pichard and R. Waksman *Catheter Cardiovasc Interv* (2009)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19360860

Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome G. Lemesle, C. Delhaye, A. Sudre, D. Broucqsaault, G. Rosey, C. Bauters and J. M. Lablanche *Am Heart J* (2009) 157; 375-82

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19185648

Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome S. Leung, D. Gallup, K. W. Mahaffey, M. Cohen, E. M. Antman, S. G. Goodman, R. A. Harrington, A. Langer, P. Aylward, J. J. Ferguson and R. M. Califf *Am Heart J* (2008) 156; 177-84

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18585514

Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction E. I. Lev, R. Kornowski, H. Vaknin-Assa, D. Brosh, S. Fuchs, A. Battler and A. Assali *Am J Cardiol* (2008) 101; 435-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18312753

Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial J. S. Li, E. Yow, K. Y. Berezny, P. M. Bokesch, M. Takahashi, T. P. Graham, Jr., S. P. Sanders, D. Sidi, D. Bonnet, P. Ewert, L. K. Jennings and A. D. Michelson *Circulation* (2008) 117; 553-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18195173

Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study W. Lieb, M. G. Larson, E. J. Benjamin, X. Yin, G. H. Tofler, J. Selhub, P. F. Jacques, T. J. Wang, J. A. Vita, D. Levy, R. S. Vasan and G. F. Mitchell *Circulation* (2009) 119; 37-43

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19103986

Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study W. Lieb, M. G. Larson, E. J. Benjamin, X. Yin, G. H. Tofler, J. Selhub, P. F. Jacques, T. J. Wang, J. A. Vita, D. Levy, R. S. Vasan and G. F. Mitchell *Circulation* (2009) 119; 37-43

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19103986

Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial R. D. Lopes, K. P. Alexander, S. V. Manoukian, M. E. Bertrand, F. Feit, H. D. White, C. V. Pollack, Jr., J. Hoekstra, B. J. Gersh, G. W. Stone and E. M. Ohman *J Am Coll Cardiol* (2009) 53; 1021-30

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19298914

Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial R. D. Lopes, K. P. Alexander, G. Marcucci, H. D. White, S. Spinler, J. Col, P. E. Aylward, R. M. Califf and K. W. Mahaffey *Eur Heart J* (2008) 29; 1827-33

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18519426

Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic M. Lotrionte, G. G. Biondi-Zoccai, P. Agostoni and I. Sheiban *Eur Heart J* (2008) 29; 138; author reply 38-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17993637

Noncardiac Surgery and Antiplatelet Therapy Following Coronary Artery Stenting M. J. Luckie, R. S. Khattar and D. G. Fraser *Heart* (2009)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19218260

Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study K. H. Mak, D. L. Bhatt, M. Shao, G. J. Hankey, J. D. Easton, K. A. Fox and E. J. Topol *Am Heart J* (2009) 157; 658-65

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19332192

Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention J. D. Marmur, S. Poludasu, J. Lazar and E. Cavusoglu *Catheter Cardiovasc Interv* (2009) 73; 214-21

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19156882

Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial A. Marzocchi, A. Manari, G. Piovaccari, C. Marrozzini, S. Marra, P. Magnavacchi, P. Sangiorgio, L. Marinucci, N. Taglieri, G. Gordini, N. Binetti, V. Guiducci, N. Franco, M. L. Reggiani and F. Saia *Eur Heart J* (2008) 29; 2972-80

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18940887

Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction S. Matetzky, P. Fefer, B. Shenkman, D. Varon, N. Savion and H. Hod *Am J Cardiol* (2008) 102; 524-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18721506

Cytochrome p-450 polymorphisms and response to clopidogrel J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. Macias, E. Braunwald and M. S. Sabatine *N Engl J Med* (2009) 360; 354-62

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19106084

Cytochrome p-450 polymorphisms and response to clopidogrel J. L. Mega, S. L. Close, S. D. Wiviott, L. Shen, R. D. Hockett, J. T. Brandt, J. R. Walker, E. M. Antman, W. Macias, E. Braunwald and M. S. Sabatine *N Engl J Med* (2009) 360; 354-62

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19106084

Abciximab in Patients With Acute ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading. A Randomized Double-Blind Trial J. Mehilli, A. Kastrati, S. Schulz, S. Frungel, S. G. Nekolla, W. Moshage, F. Dotzer, K. Huber, J. Pache, J. Dirschinger, M. Seyfarth, S. Martinoff, M. Schwaiger and A. Schomig *Circulation* (2009)

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation>

n&list_uids=19332467

The Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale R. Mehran, B. Brodie, D. A. Cox, C. L. Grines, B. Rutherford, D. L. Bhatt, G. Dangas, F. Feit, E. M. Ohman, H. Parise, M. Fahy, A. J. Lansky and G. W. Stone *Am Heart J* (2008) 156; 44-56
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18585496

Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials S. R. Mehta, W. E. Boden, J. W. Eikelboom, M. Flather, P. G. Steg, A. Avezum, R. Afzal, L. S. Piegas, D. P. Faxon, P. Widimsky, A. Budaj, S. Chrolavicius, H. J. Rupprecht, S. Jolly, C. B. Granger, K. A. Fox, J. P. Bassand and S. Yusuf *Circulation* (2008) 118; 2038-46
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18955665

Transient ST-elevation myocardial infarction: clinical course with intense medical therapy and early invasive approach, and comparison with persistent ST-elevation myocardial infarction S. R. Meisel, Y. Dagan, D. S. Blondheim, S. Dacca, M. Shochat, M. Kazatsker, A. Asif, A. Frimerman and A. Shotan *Am Heart J* (2008) 155; 848-54
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18440331

Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes C. Melloni, K. P. Alexander, A. Y. Chen, L. K. Newby, M. T. Roe, N. M. Allen LaPointe, C. V. Pollack, Jr., W. B. Gibler, E. M. Ohman and E. D. Peterson *Am Heart J* (2008) 156; 209-15
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18657648

Cytochrome P450 2C19 polymorphism and clopidogrel after MI J. Miao, R. Liu and Z. Li *Lancet* (2009) 373; 1171-2; author reply 72-3
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19345824

Mechanical reperfusion: treat well, treat on time too G. Montalescot *Lancet* (2008) 372; 509-10
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18707968

Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial G. Montalescot, M. Cohen, G. Salette, W. J. Desmet, C. Macaya, P. E. Aylward, P. G. Steg, H. D. White, R. Gallo and S. R. Steinhubl *Eur Heart J* (2008) 29; 462-71
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18276619

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial G. Montalescot, S. D. Wiviott, E. Braunwald, S. A. Murphy, C. M. Gibson, C. H. McCabe and E. M. Antman *Lancet* (2009) 373; 723-31

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19249633

Antithrombotic therapy to support primary PCI D. A. Morrow *N Engl J Med* (2008) 358; 2280-2

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18499573

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial S. A. Murphy, E. M. Antman, S. D. Wiviott, G. Weerakkody, G. Morocutti, K. Huber, J. Lopez-Sendon, C. H. McCabe and E. Braunwald *Eur Heart J* (2008) 29; 2473-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18682445

Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction M. Nahrendorf, E. Aikawa, J. L. Figueiredo, L. Stangenberg, S. W. van den Borne, W. M. Blankesteyn, D. E. Sosnovik, F. A. Jaffer, C. H. Tung and R. Weissleder *Eur Heart J* (2008) 29; 445-54

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18276618

A thrombus stuck in the ostium of the coronary artery T. Nakahara, M. Manita and M. Kurabayashi *Eur Heart J* (2009) 30; 24

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18664459

Optimal treatment of renal artery in-stent restenosis: repeat stent placement versus angioplasty alone Z. M. N'Dandu, R. A. Badawi, C. J. White, M. A. Grise, J. P. Reilly, J. S. Jenkins, T. J. Collins and S. R. Ramee *Catheter Cardiovasc Interv* (2008) 71; 701-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18360868

One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial G. Ndrepepa, A. Kastrati, J. Mehilli, F. J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, M. Seyfarth, J. Pache, J. Dirschinger, P. B. Berger and A. Schomig *Eur Heart J* (2008) 29; 455-61

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18158289

Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study T. Ninomiya, Y. Kiyohara, Y. Tokuda, Y. Doi, H. Arima, A. Harada, Y. Ohashi and H. Ueshima *Circulation* (2008) 118; 2694-701

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19106392

Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy M. O'Donoghue, D. A. Morrow, C. P. Cannon, W. Guo, S. A. Murphy, C. M. Gibson and M. S. Sabatine *Eur Heart J* (2008) 29; 984-91

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18346960

Clopidogrel treatment and the MEND-CABG II trial J. Oh, N. Hong and S. M. Kang
JAMA (2008) 300; 1021; author reply 21-2

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18768409

Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals J. Oldgren, N. Johnston and A. Siegbahn Am Heart J (2008) 155; 493 e1-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18294482

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment J. Oldgren, L. Wallentin, R. Afzal, J. P. Bassand, A. Budaj, S. Chrolavicius, K. A. Fox, C. B. Granger, S. R. Mehta, P. Pais, R. J. Peters, D. Xavier, J. Zhu and S. Yusuf Eur Heart J (2008) 29; 315-23

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18084015

Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network P. Ortolani, A. Marzocchi, C. Marrozzini, T. Palmerini, F. Saia, N. Taglieri, F. Baldazzi, G. Dall'Ara, P. Nardini, S. Gianstefani, P. Guastaroba, R. Grilli and A. Branzi Eur Heart J (2009) 30; 33-43

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18996956

Prasugrel versus clopidogrel V. Pasceri, G. Patti and G. Di Sciascio N Engl J Med (2008) 358; 1298-9; author reply 99-301

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18357638

Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio and G. Di Sciascio J Am Coll Cardiol (2008) 52; 1128-33

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18804738

The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial R. J. Peters, C. Joyner, J. P. Bassand, R. Afzal, S. Chrolavicius, S. R. Mehta, J. Oldgren, L. Wallentin, A. Budaj, K. A. Fox and S. Yusuf Eur Heart J (2008) 29; 324-31

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18245119

Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors E. Pezalla, D. Day and I. Pulliadath J Am Coll Cardiol (2008) 52; 1038-9; author reply 39

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18786491

Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes D. S. Pinto, G. W. Stone, C. Shi, E. S. Dunn, M. R. Reynolds, M. York, J. Walczak, R. H. Berezin, R. Mehran, B. T. McLaurin, D. A. Cox, E. M. Ohman, A. M. Lincoff and D. J. Cohen *J Am Coll Cardiol* (2008) 52; 1758-68

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19022155

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation M. J. Price, S.

Endemann, R. R. Gollapudi, R. Valencia, C. T. Stinis, J. P. Levisay, A. Ernst, N. S.

Sawhney, R. A. Schatz and P. S. Teirstein *Eur Heart J* (2008) 29; 992-1000

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18263931

Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers M. J. Price and P. S. Teirstein *Am J Cardiol* (2008) 102; 790-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18774008

Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease R. Qayyum, D. M. Becker, L. R. Yanek, T. F. Moy, L. C. Becker, N. Faraday and D. Vaidya *Am J Cardiol* (2008) 101; 1359-63

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18435972

Clinical follow-up in endovascular treatment for TASC C-D lesions in femoro-popliteal segment M. Rabellino, T. Zander, S. Baldi, L. Garcia Nielsen, F. J. Aragon-Sanchez, I. Zerolo, R. Llorens and M. Maynar *Catheter Cardiovasc Interv* (2009) 73; 701-5

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19309709

Cytochrome P450 2C19 polymorphism and clopidogrel after MI R. Ramaraj *Lancet* (2009) 373; 1172; author reply 72-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19345827

Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era? M. Roffi and D. Mukherjee *Eur Heart J* (2008) 29; 429-31

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18276614

Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy R. Rossini, G. Musumeci, C. Lettieri, M. Molfese, L. Mihalcsik, P. Mantovani, V. Sirbu, T. A. Bass, F. Della Rovere, A. Gavazzi and D. J. Angiolillo *Am J Cardiol* (2008) 102; 1618-23

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19064015

Which patients receiving warfarin can be treated safely with a drug-eluting stent? A. D. Ryding and A. P. Banning *Heart* (2008) 94; 275-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18276815

Efficacy and safety of clopidogrel pretreatment before percutaneous coronary

intervention with and without glycoprotein IIb/IIIa inhibitor use M. S. Sabatine, H. N. Hamdalla, S. R. Mehta, K. A. Fox, E. J. Topol, S. R. Steinhubl and C. P. Cannon *Am Heart J* (2008) 155; 910-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18440341

The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study J. Saw, E. H. Madsen, S. Chan and E. Maurer-Spurej *J Am Coll Cardiol* (2008) 52; 1826-33

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19038679

Prasugrel versus clopidogrel V. Serebruany *N Engl J Med* (2008) 358; 1298; author reply 99-301

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18354110

The challenge of monitoring platelet response after clopidogrel V. L. Serebruany and S. Goto *Eur Heart J* (2008) 29; 2833-4

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18977768

Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial V. L. Serebruany, A. I. Malinin, A. Pokov, G. Barsness and D. F. Hanley *Am Heart J* (2008) 155; 93 e1-7

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18082496

Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease M. H. Shishehbor, L. P. Oliveira, M. S. Lauer, D. L. Sprecher, K. Wolski, L. Cho, B. J. Hoogwerf and S. L. Hazen *Am J Cardiol* (2008) 101; 1741-6

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18549850

Multiple mechanisms affect the clopidogrel response G. Siasos, D. Tousoulis and C. Stefanadis *J Am Coll Cardiol* (2009) 53; 900-1; author reply 01

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19264256

Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, A. Schomig, A. Kastrati and N. von Beckerath *J Am Coll Cardiol* (2009) 53; 849-56

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19264241

Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention D. Sibbing, G. Busch, S. Braun, S. Jawansky, A. Schomig, A. Kastrati, I. Ott and N. von Beckerath *Eur Heart J* (2008) 29; 1504-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18467322

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel J. M. Siller-Matula,

I. Lang, G. Christ and B. Jilma *J Am Coll Cardiol* (2008) 52; 1557-63
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19007592

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel J. M. Siller-Matula, A. O. Spiel, I. M. Lang, G. Kreiner, G. Christ and B. Jilma *Am Heart J* (2009) 157; 148 e1-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19081411

Genetic determinants of response to clopidogrel and cardiovascular events T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. G. Steg, J. Ferrieres, N. Danchin and L. Becquemont *N Engl J Med* (2009) 360; 363-75
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19106083

The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention E. Stabile, W. Nammas, L. Salemme, G. Sorropago, A. Cioppa, T. Tesorio, V. Ambrosini, E. Campopiano, G. Popusoi, G. Biondi Zoccai and P. Rubino *J Am Coll Cardiol* (2008) 52; 1293-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18929239

Aspirin following PCI: too much of a good thing? S. R. Steinhubl and P. B. Berger *Eur Heart J* (2009)
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19293194

Bivalirudin during primary PCI in acute myocardial infarction G. W. Stone, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B. J. Gersh, S. J. Pocock, G. Dangas, S. C. Wong, A. J. Kirtane, H. Parise and R. Mehran *N Engl J Med* (2008) 358; 2218-30
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18499566

Clopidogrel in acute coronary syndrome: to genotype or not? R. F. Storey *Lancet* (2009) 373; 276-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19108882

Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial) N. Taglieri, F. Saia, V. Guiducci, S. Tondi, F. Conrotto, C. Marrozzini, G. Rocchi, E. Biagini, M. L. Reggiani, P. Giacometti, G. Piovaccari, A. Manari and A. Marzocchi *Am J Cardiol* (2009) 103; 785-90
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19268732

Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration C. J. Terkelsen, C. Oxvig, B. L. Norgaard, S. Glerup, T. S. Poulsen, J. F. Lassen, H. J. Moller, L. Thuesen, E. Falk, T. T. Nielsen and H. R. Andersen *Am J Cardiol* (2009) 103; 29-35

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19101225

Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial H. Thiele, K. Schindler, J. Friedenberger, I. Eitel, G. Furnau, E. Grebe, S. Erbs, A. Linke, S. Mobius-Winkler, D. Kivelitz and G. Schuler *Circulation* (2008) 118; 49-57

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18559698

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents D. Trenk, W. Hochholzer, M. F. Fromm, L. E. Chialda, A. Pahl, C. M. Valina, C. Stratz, P. Schmiebusch, H. P. Bestehorn, H. J. Buttner and F. J. Neumann *J Am Coll Cardiol* (2008) 51; 1925-34

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18482659

Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome P. J. van den Bergh, P. C. Kievit, M. A. Brouwer, W. R. Aengevaeren, G. Veen and F. W. Verheugt *Am Heart J* (2009) 157; 532-40

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19249425

Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial A. W. Van't Hof, J. Ten Berg, T. Heestermans, T. Dill, R. C. Funck, W. van Werkum, J. H. Dambrink, H. Suryapranata, G. van Houwelingen, J. P. Ottervanger, P. Stella, E. Giannitsis and C. Hamm *Lancet* (2008) 372; 537-46

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18707985

Assessment of P2Y₁₂ inhibition with the point-of-care device VerifyNow P2Y₁₂ in patients treated with prasugrel or clopidogrel coadministered with aspirin C. Varenhorst, S. James, D. Erlinge, O. O. Braun, J. T. Brandt, K. J. Winters, J. A. Jakubowski, S. Olofsson, L. Wallentin and A. Siegbahn *Am Heart J* (2009) 157; 562 e1-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19249429

Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review P. J. Vlaar, T. Svilaas, K. Damman, B. J. de Smet, J. G. Tijssen, H. L. Hillege and F. Zijlstra *Circulation* (2008) 118; 1828-36

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18852370

Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study P. J. Vlaar, T. Svilaas, I. C. van der Horst, G. F. Diercks, M. L. Fokkema, B. J. de Smet, A. F. van den Heuvel, R. L. Anthonio, G. A. Jessurun, E. S.

Tan, A. J. Suurmeijer and F. Zijlstra *Lancet* (2008) 371; 1915-20
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18539223

Prasugrel versus clopidogrel F. von Lewinski, J. Riggert and W. Paulus *N Engl J Med* (2008) 358; 1299; author reply 99-301
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18357639

Prasugrel achieves greater and faster P2Y₁₂receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O. O. Braun, J. A. Jakubowski, A. Sugidachi, K. J. Winters and A. Siegbahn *Eur Heart J* (2008) 29; 21-30

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18055486

Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative T. Y. Wang, A. Y. Chen, E. D. Peterson, R. C. Becker, W. B. Gibler, E. M. Ohman and M. T. Roe *Eur Heart J* (2008) 29; 1103-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18353757

Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry T. Y. Wang, L. A. Robinson, F. S. Ou, M. T. Roe, E. M. Ohman, W. B. Gibler, S. C. Smith, Jr., E. D. Peterson and R. C. Becker *Am Heart J* (2008) 155; 361-8

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18215609

Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial H. D. White, D. P. Chew, J. W. Hoekstra, C. D. Miller, C. V. Pollack, Jr., F. Feit, A. M. Lincoff, M. Bertrand, S. Pocock, J. Ware, E. M. Ohman, R. Mehran and G. W. Stone *J Am Coll Cardiol* (2008) 51; 1734-41

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18452778

The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an international randomized Evaluation (STEEPLE) trial H. D. White, R. Gallo, M. Cohen, P. G. Steg, P. E. Aylward, C. Bode, S. Steinhubl and G. Montalescot *Am Heart J* (2009) 157; 125-31

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19081408

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial H. D. White, E. M. Ohman, A. M. Lincoff, M. E. Bertrand, A. Colombo, B. T. McLaurin, D. A. Cox, S. J. Pocock, J. A. Ware, S. V. Manoukian, A. J. Lansky, R.

Mehran, J. W. Moses and G. W. Stone *J Am Coll Cardiol* (2008) 52; 807-14
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18755342

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 S. D. Wiviott, E. Braunwald, D. J. Angiolillo, S. Meisel, A. J. Dalby, F. W. Verheugt, S. G. Goodman, R. Corbalan, D. A. Purdy, S. A. Murphy, C. H. McCabe and E. M. Antman *Circulation* (2008) 118; 1626-36

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18757948

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial S. D. Wiviott, E. Braunwald, C. H. McCabe, I. Horvath, M. Keltai, J. P. Herrman, F. Van de Werf, W. E. Downey, B. M. Scirica, S. A. Murphy and E. M. Antman *Lancet* (2008) 371; 1353-63

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18377975

Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad Y. Yano, T. Ohmori, S. Hoshida, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario and Y. Sakata *Eur Heart J* (2008) 29; 1729-38

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18270211

Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes R. W. Yeh, S. J. Baron, J. L. Healy, E. Pomerantsev, I. A. McNulty, I. Cruz-Gonzalez and I. K. Jang *Catheter Cardiovasc Interv* (2009)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19213062

Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial G. Yong, J. Rankin, L. Ferguson, J. Thom, J. French, D. Brieger, D. P. Chew, R. Dick, D. Eccleston, B. Hockings, D. Walters, A. Whelan and J. W. Eikelboom *Am Heart J* (2009) 157; 60 e1-9

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19081397

The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ? F. Zijlstra *Catheter Cardiovasc Interv* (2009) 73; 222-3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19156883